Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt*, Marjolein de Bruin-Weller, Melinda Gooderham, Jennifer C. Cather, Jamie Weisman, David Pariser, Eric L. Simpson, Kim A. Papp, H. Chih Ho Hong, Diana Rubel, Peter Foley, Errol Prens, Christopher E.M. Griffiths, Takafumi Etoh, Pedro Herranz Pinto, Ramon M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping ZhuBolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    1042 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science